Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

Published:2009-09 Issue:9692 Volume:374 Page:787-795
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Sabatine Marc S,Antman Elliott M,Widimsky Petr,Ebrahim Iftikhar O,Kiss Robert G,Saaiman André,Polasek Rostislav,Contant Charles F,McCabe Carolyn H,Braunwald Eugene

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Mechanisms of thrombus formation;Furie;N Engl J Med,2008

2. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity;Andersen;Proc Natl Acad Sci USA,1999

3. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina;Oler;JAMA,1996

4. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

5. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy;Hirsh;Chest,2004

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N‐Pyridylureas as Masked Isocyanates Fort the Late‐Stage Diversification of Pyridine‐N‐Oxides;ChemistrySelect;2024-03-27

2. Trends in Off-Label Indications of Non-Vitamin K Antagonist Oral Anticoagulants in Acute Coronary Syndrome;Reviews in Cardiovascular Medicine;2023-06-25

3. Direct thrombin inhibitors and factor Xa inhibitors for acute coronary syndromes: a network meta-analysis;Cochrane Database of Systematic Reviews;2022-09-26

4. Translational Medicine – The Bridging Discipline. Role and Tools in the Drug Development Process;Principles of Biomedical Sciences and Industry;2022-07-22

5. Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease;Interventional Cardiology;2022-05-06